ENDPOINTS

J&J, Protagonist outline first IBD win for potential immunological blockbuster

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the drug, known ...

Mar 10, 2025 - 16:07
 0
J&J, Protagonist outline first IBD win for potential immunological blockbuster
Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the drug, known ...
Read More

Tags:

Previous Article

Lila Sciences Uses A.I. to Turbocharge Scientific Discovery

Next Article

CIO Podcast – Episode 91: Sustainability Through Technology with Her Excellency ...

Related Posts

Compounders sue FDA over end of semaglutide shortage

Compounders sue FDA over end of semaglutide shortage

Feb 25, 2025  0

Beam shares promising first clinical data on gene editing treatment

Beam shares promising first clinical data on gene editi...

Mar 10, 2025  0

Misleading promotion lands NJ drugmaker a letter from FDA

Misleading promotion lands NJ drugmaker a letter from FDA

Mar 4, 2025  0